Premium
Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review
Author(s) -
Prasher Parteek,
Sharma Mousmee,
Aljabali Alaa A. A.,
Gupta Gaurav,
Negi Poonam,
Kapoor Deepak N.,
Singh Inderbir,
Zacconi Flavia C.,
Jesus Andreoli Pinto Terezinha,
Silva Mateus Webba,
Bakshi Hamid A.,
Chellappan Dinesh Kumar,
Tambuwala Murtaza M.,
Dua Kamal
Publication year - 2020
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21704
Subject(s) - pharmacophore , triazine , efflux , combinatorial chemistry , chemistry , drug , drug development , computational biology , pharmacology , nanotechnology , biology , stereochemistry , materials science , biochemistry , organic chemistry
Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux‐pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5‐triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5‐triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5‐triazine based hybrid molecules in the development of pharmaceuticals.